Allogene Therapeutics (ALLO) Long-Term Investments (2018 - 2025)

Allogene Therapeutics (ALLO) has 8 years of Long-Term Investments data on file, last reported at $8.0 million in Q4 2025.

• For the quarter ending Q4 2025, Long-Term Investments fell 90.03% year-over-year to $8.0 million; the trailing twelve-month figure through Dec 2025 stood at $8.0 million (down 90.03% YoY), and the FY2025 full-year result was $8.0 million, down 90.03% from the prior year.
• Long-Term Investments slipped to $8.0 million in Q4 2025, from $24.9 million in the prior quarter.
• In the past five years, Long-Term Investments ranged from a high of $378.2 million in Q3 2021 to a low of $1.1 million in Q2 2024.
• A 5-year average of $66.9 million and a median of $24.9 million in 2025 frame the typical range for Long-Term Investments.
• Across the five-year window, Long-Term Investments jumped 8275.16% in 2021 and tumbled 97.84% in 2024, its largest moves.
• Tracing ALLO's Long-Term Investments over 5 years: stood at $352.2 million in 2021, then slumped by 95.08% to $17.3 million in 2022, then surged by 85.77% to $32.2 million in 2023, then soared by 150.77% to $80.7 million in 2024, then sank by 90.03% to $8.0 million in 2025.
• Business Quant data shows ALLO's Long-Term Investments at $8.0 million in Q4 2025, $24.9 million in Q3 2025, and $29.5 million in Q2 2025.